Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 5, 2003, Pages 821-825

  Weinberg, Adriana ^a,b   Pott, Gregory B ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOKINE; CYTOMEGALOVIRUS ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL; T LYMPHOCYTE; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; MALE; VIRAL LOAD;

EID: 0141563837     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.5.821-825.2003     Document Type: Article

References (36)

1. Al-Harthi, L., J. Siegel, J. Spritzler, J. Pottage, M. Agnoli, and A. Landay. 2000. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 14:761-770.
2. Angel, J. B., K. G. Parato, A. Kumar, S. Kravcik, A. D. Badley, C. Fex, D. Ashby, E. Sun, and D. W. Cameron. 2001. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J. Infect. Dis. 183:546-554.
3. Bess, J. W., R. J. Gorelick, W. J. Bosche, L. E. Henderson, and L. O. Arthur. 1997. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230:134-144.
4. Binley, J. M., D. S. Schiller, G. M. Ortiz, A. Hurley, D. F. Nixon, M. M. Markowitz, and J. P. Moore. 2000. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J. Infect. Dis. 181:1249-1263.
5. Blankson, J. N., J. E. Gallant, and R. F. Siliciano. 2001. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J. Infect. Dis. 183:657-661.
6. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
7. Chougnet, C., S. Jankelevich, K. Fowke, D. Liewehr, S. M. Steinberg, B. U. Mueller, P. A. Pizzo, R. Yarchoan, and G. M. Shearer. 2001. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. J. Infect. Dis. 184:201-205.
8. Connick, E., M. M. Lederman, B. L. Kotzin, J. Spritzler, D. R. Kuritzkes, M. St Clair, A. D. Sevin, L. Fox, M. H. Chiozzi, J. M. Leonard, F. Rousseau, J. D'Arc Roe, A. Martinez, H. Kessler, and A. Landay. 2000. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J. Infect. Dis. 181:358-363.
9. + T cells. Nature 417:95-98.
10. Douek, D. C., R. A. Koup, R. D. McFarland, J. L. Sullivan, and K. Luzuriaga. 2000. Effect of HIV on thymic function before and after antiretroviral therapy in children. J. Infect. Dis. 181:1479-1482.
11. Dybul, M., G. Mercier, M. Belson, C. W. Hallahan, S. Liu, C. Perry, B. Herpin, L. Ehler, R. T. Davey, J. A. Metcalf, J. M. Mican, R. A. Seder, and A. S. Fauci. 2000. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-γ in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness. J. Immunol. 165:1685-1691.
12. Gibb, D. M., A. Newberry, N. Klein, A. de Rossi, I. Grosch-Woerner, A. Babiker, et al. 2000. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 255:1331-1332.
13. Greenough, T. C., D. B. Brettler, F. Kirchhoff, L. Alexander, R. C. Desrosiers, S. J. O'Brien, M. Somasundaran, K. Luzuriaga, and J. L. Sullivan. 1999. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J. Infect. Dis. 180:1790-1802.
14. Haslett, P. A., D. F. Nixon, Z. Shen, M. Larsson, W. I. Cox, R. Manandhar, S. M. Donahoe, and G. Kaplan. 2000. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J. Infect. Dis. 181:1264-1272.
15. Havlir, D. V., R. D. Schrier, F. J. Torriani, K. Chervenak, J. Y. Hwang, and W. H. Boom. 2000. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J. Infect. Dis. 182:1658-1663.
16. Johnston, A. M., M. E. Valentine, J. Ottinger, R. Baydo, V. Gryszowka, C. Vavro, K. Weinhold, M. St Clair, and R. E. MeKinney. 2001. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr. Infect. Dis. J. 20:941-946.
17. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173:321-329.
18. Li, T. S., R. Tubiana, C. Katlama, V. Calvez, H. Ait Mohand, and B. Autran. 1998. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351:1682-1686.
19. Luzuriaga, K., M. McManus, M. Catalina, S. Mayack, M. Sharkey, M. Stevenson, and J. L. Sullivan. 2000. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J. Virol. 74:6984-6991.
20. Malhotra, U., M. M. Berrey, Y. Huang, J. Markee, D. J. Brown, S. Ap, L. Musey, T. Schacker, L. Corey, and M. J. McElrath. 2000. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:121-131.
21. McMichael, A. J., and S. L. Rowland-Jones. 2000. Cellular immune responses to HIV. Nature 410:980-987.
22. Ostrowski, M. A., J. X. Gu, C. Kovacs, J. Freedman, M. A. Luscher, and K. S. MacDonald. 2001. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-γ and interleukin-10 responses. J. Infect. Dis. 184:1268-1278.
23. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
24. Pontesilli, O., S. Kerkhof-Garde, D. W. Notermans, N. A. Foudraine, M. T. Roos, M. R. Klein, S. A. Danner, J. M. Lange, and F. Miedema. 1999. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J. Infect. Dis. 180:76-86.
25. Pontesilli, O., M. R. Klein, S. R. Kerkhof-Garde, N. G. Pakker, F. de Wolf, H. Schuitemaker, and F. Miedema. 1998. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178:1008-1018.
26. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, L. O. Arthur, L. E. Henderson, and J. D. Lifson. 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
27. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. USA 87:6058-6062.
28. Schooley, R. T. 1999. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin. Infect. Dis. 29:12-28.
29. Sester, M., U. Sester, H. Kohler, T. Schneider, L. Deml, R. Wagner, N. Mueller-Lantzsch, H. W. Pees, and A. Meyerhans. 2000. Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS 14:2653-2660.
30. Sieg, S. F., D. A. Bazdar, C. V. Harding, and M. M. Lederman. 2001. Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease. J. Virol. 75:9983-9985.
31. Sieg, S. F., C. V. Harding, and M. M. Lederman. 2001. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. J. Clin. Investig. 108:757-764.
32. Smith, J. G., X. Liu, R. M. Kaufhold, J. Clair, and M. J. Caulfield. 2001. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diag. Lab. Immunol. 8:871-879.
33. Spiegel, H. M., E. DeFalcon, G. S. Ogg, M. Larsson, T. J. Beadle, P. Tao, A. J. McMichael, N. Bhardwaj, C. O'Callaghan, W. I. Cox, K. Krasinski, H. Pollack, W. Borkowsky, and D. F. Nixon. 1999. Changes in frequency of HIV -1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J. Infect. Dis. 180:359-368.
34. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Investig. 99:1739-1750.
35. Weinberg, A., D. A. Wohl, R. J. Barrett, and C. van der Hoost. 2001. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J. Infect. Dis. 184:707-712.
36. Weinberg, A., D. A. Wohl, D. G. Brown, G. B. Pott, L. Zhang, M. G. Ray, and C. van der Hoost. 2002. Effect of cryopreservation on measurement of cytomegalovirus-specific cellular immune response in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 25:109-114.